ARROW
IMPORTANT SAFETY INFORMATION
Contraindications
ARROW
IMPORTANT SAFETY INFORMATION
Contraindications
Warnings and precautions
Skin and Hypersensitivity Reactions:
Hepatotoxicity:
Embryo-Fetal Toxicity:
Depressive Disorders:
Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions:
Adverse reactions
The most common adverse reactions (incidence ≥2%, all Grades) with JULUCA were diarrhea (2%), headache (2%), and nausea (2%).
Drug interactions
Use in specific populations
JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA should be taken with a meal
Please see full Prescribing Information for JULUCA.
DGRWCNT210009
To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at
1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for JULUCA.
Trademarks are owned by or licensed to the ViiV Healthcare group of companies. The other brands listed are trademarks of their respective owners and are not trademarks of the ViiV Healthcare group of companies. The makers of these brands are not affiliated with and do not endorse the ViiV Healthcare group of companies or its products. This site is funded and developed by ViiV Healthcare. This site is intended for US healthcare professionals only. ©2021 ViiV Healthcare or licensor.
DGRWCNT210009 October 2021
Produced in USA.